PATENT CLAIM ANALYSIS

Application Number: 15767813
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "027000"]

Abstract:
Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation using a combination of an inhibitor of a mutant IDH1 enzyme and an AML induction and consolidation therapy.

Claim (Index 9):
The method of  claim 8 , wherein the dose of cytarabine is between about 1 g/m 2  and about 5 g/m 2 .

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.26923
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15767822', '15125880', '15368405', '12730097', '12761588']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7349367836886439
- 35 USC 102 Novelty (BERT): 0.5337790525507906
- Combined Prediction Score: 0.7148210105748586
- Mean Citation Score: 284.5714260000001
- Max Citation Score: 329.0274
- Similarity Product: 217.0061226405859

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test